Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | HuCART19-IL18 |
Trade Name | |
Synonyms | Autologous Anti-CD19 CAR IL-18-expressing T Cells |
Drug Descriptions |
HuCART19-IL18 are autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD19 and to secrete IL18, which may increase anti-tumor immune response and induce cytotoxicity against CD19-expressing tumor cells (Hematol. Oncol. 2023; 41: 35-37, NCI Drug Dictionary). |
DrugClasses | CD19 Immune Cell Therapy 62 |
CAS Registry Number | NA |
NCIT ID | C179603 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
HuCART19-IL18 | HuCART19-IL18 | 0 | 2 |